Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to September 2004

Novel Fiber Limits Sugar Absorption

September 2004

References
  1. Available at: http://www.health-alliance.com/hospitals/Jewish/glueck/insulin_resistance.htm. Accessed June 24, 2004.
  2. Hano T, Nishio I. Treatment of hypertension in the patients with obesity. Nippon Rinsho. 2001 May;59(5):973-7.
  3. Kopf D, Muhlen I, Kroning G, Sendzik I, Huschke B, Lehnert H. Insulin sensitivity and sodium excretion in normotensive offspring and hypertensive patients. Metabolism. 2001 Aug;50(8):929-35.
  4. Noda M, Matsuo T, Nagano-Tsuge H, et al. Involvement of angiotensin II in progression of renal injury in rats with genetic noninsulin-dependent diabetes mellitus (Wistar fatty rats). Jpn J Pharmacol. 2001 Apr;85(4):416-22.
  5. Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation. 2001 May 8;103(18):2225-9.
  6. Katz AS, Goff DC, Feldman SR. Acanthosis nigricans in obese patients: Presentations and implications for prevention of atherosclerotic vascular disease. Dermatol Online J. 2000 Sep;6(1):1.
  7. Kaaks R. Plasma insulin, IGF-I and breast cancer. Gynecol Obstet Fertil. 2001 Mar;29(3):185-91.
  8. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer. 2001 Feb 2;84(3):417-22.
  9. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetier P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. Diabetes Care. 2001 May;24(5):843-9.
  10. Czyzyk A, Szczepanik Z. Diabetes mellitus and cancer. Eur J Intern Med. 2000 Oct;11(5):245-52.
  11. Bruce WR, Wolever TM, Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer. 2000;37(1):19-26.
  12. Cook DG, Leverenz JB, McMillian PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol. 2003 Jan;162(1):313-9.
  13. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001 Feb;39(2):151-8.
  14. Chu N, Spiegelman D, Hotamisligil GS, Rifai N, Stampler M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis. 2001 Aug;157(2):495-503.
  15. Johnson MS, Figueroa-Colon R, Huang TT, Dwyer JH, Goran MI. Longitudinal changes in body fat in African-American and caucasian children: influence of fasting insulin and insulin sensitivity. J Clin Endocrinol Metab. 2001 Jul;86(7):3182-7.
  16. Danadian K, Lewy V, Janosky JJ, Arslanian S. Lipolysis in African-American children: is it a metabolic risk factor predisposing to obesity? J Clin Endocrinol Metab. 2001 Jul;86(7):3022-6.
  17. Zoltowska M, Ziv E, Delvin E, et al. Circulating lipoproteins and hepatic sterol metabolism in Psammomys obesus prone to obesity, hyperglycemia and hyperinsulinemia. Atherosclerosis. 2001 Jul;157(1):85-96.
  18. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci. 2001 Apr;321(4):242-8.
  19. Emdin M, Gastaldelli A, Muscelli E, et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation. 2001 Jan 30;103(4):513-9.
  20. Despres JP, Pascot A, Lemieux I. Risk factors associated with obesity: a metabolic perspective. Ann Endocrinol. 2000 Dec;61 Suppl 6:31-8.
  21. Pyorala M, Miettinen H, Laakso M, Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care. 2000 Aug;23(8):1097-102.
  22. Gastaldelli A, Toschi E, Pettiti M, et al. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes. 2001 Aug;50(8):1807-12.
  23. Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab. 2001 Jun;280(6):E1000-6.
  24. O’Keefe JH Jr, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999 Feb;74(2):171-80.
  25. Heller RF, Heller RF. Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor. Med Hypotheses. 1994 May;42(5):307-12.
  26. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes. 1990 Mar;39(3):283-9.
  27. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002 May 8;287(18):2414-23.
  28. Blüher M, Kahn BB, Kahn RC. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003 Jan 24;299(5606):572-4.
  29. Bell DS. Importance of postprandial glucose control. South Med J. 2001 Aug;94(8):804-9.
  30. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J. 2004 May;147(5):803-7.
  31. Lebovitz HE. Effect of the postprandial state on nontraditional risk factors. Am J Cardiol. 2001 Sep 20;88(6A):20H-5H.
  32. Sasso FC, Carbonara O, Nasti R, et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. JAMA. 2004 Apr 21;291(15):1858-63.
  33. Marlett JA, McBurney MI, Slavin JL. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2002 Jul;102(7):993-1000.
  34. Jenkins DJ, Kendall CW, Vuksan V, et al. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr. 2002 May;75(5):834-9.
  35. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care. 2000 Jan;23(1):9-14.
  36. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999 Jun;22(6):913-9.
  37. Kim E, Vuksan V, et al. The relationship between viscosity of dietary fibers and their hypoglycemic effects. Kor J Nutr. 1996;29:615-21.
  38. Gonzalez Canga A, Fernandez Martinez N, Sahagun AM, et al. Glucomannan: properties and therapeutic applications. Nutr Hosp. 2004 Jan-Feb;19(1):45-50.
  39. McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses. 2002 Jun;58(6):487-90.
  40. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8(4):289-93.
  41. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. Minerva Med. 1992 Mar;83(3):135-9.
  42. Cairella M, Marchini G. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter. 1995 Apr;146(4):269-74.
  43. Livieri C, Novazi F, Lorini R. The use of highly purified glucomannan-based fibers in childhood obesity. Pediatr Med Chir. 1992 Mar-Apr;14(2):195-8.
  44. Vuksan V, PhD, associate director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital and faculty of medicine, University of Toronto, Canada.
  45. Victoroff J. Saving Your Brain: The Revolutionary Plan to Boost Brain Power, Improve Memory and Protect Yourself Against Aging and Alzheimer’s. New York, NY: Bantam Books; 2002.
  46. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001 Jan 18;409(6818):307-12.
  47. Flier JS. Diabetes: The missing link with obesity? Nature. 2001 Jan 18;409(6818):292-3.
  48. Andallu B, Suryakantham V, Srikanthi BL, Reddy GK. Effect of mulberry (Morus indica L.) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes. Clin Chim Acta. 2001 Dec;314(1-2):47-53.
  49. Andallu B, Varadacharyulu NCh. Antioxidant role of mulberry (Morus indica L. cv. Anantha) leaves in streptozotocin-diabetic rats. Clin Chim Acta. 2003 Dec;338(1-2):3-10.
  50. Sharma R, Sharma A, Shono T, et al. Mulberry moracins: scavengers of UV stress-generated free radicals. Biosci Biotechnol Biochem. 2001 Jun;65(6):1402-5.
  51. Doi K, Kojima T, Fujimoto Y. Mulberry leaf extract inhibits the oxidative modification of rabbit and human low density lipoprotein. Biol Pharm Bull. 2000 Sept;23(9):1066-71.
  52. Andallu B, Varadacharyulu NCh. Control of hyperglycemia and retardation of cataract by mulberry (Morus indica L.) leaves in streptozotocin diabetic rats. Indian J Exp Biol. 2002 Jul;40(7):791-5.
  53. Vuksan V, Lyon M, Breitman P, Sievenpiper J. Three-week consumption of a highly viscous dietary fiber blend results in improvements in insulin sensitivity and reductions in body fat. Results of a double blind, placebo controlled trial. Presented at the 64th Annual Meeting of the American Diabetes Association. Orlando, FL; June 4-8, 2004.
  54. Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Nutr Rev. 2001 May;59(5):129-39.
  55. Murray M. How to prevent and treat diabetes with natural medicines. New York: Riverhead Books; 2003:183-555.
  56. Jenkins DJ, Kendall CW, Axelsen M, Augustin LS, Vuksan V. Viscous and nonviscous fibers, nonabsorbable and low glycemic index carbohydrates, blood lipids and coronary heart disease. Curr Opin Lipidol. 2000 Feb;11(1):49-56.
  57. Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem. 2004 Jun;11(12):1595-615.
  58. Wulffele MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 2002 Dec;25(12):2133-40.
  59. Knowler WC, Barrett-Conner E, Fowler SW, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med. 2002 Feb 7;34(6):393-403.
  60. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001 Apr;107 (4):E55.
  61. Klow NE, Draganov B, Os I. Metformin and contrast media-increased risk of lactic acidosis. Tidsskr Nor Laegeforen. 2001 Jun 10;121(15):1829.
  62. Charles MA, Eschwege E. Prevention of type 2 diabetes: role of metformin. Drugs. 1999;58(Suppl. 1):71-3.
  63. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998 Oct;21(10):1659-63.
  64. Abbasi F, Kamath V, Rizvi AA, Carantoni M, Chen YD, Reaven GM. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care. 1997 Dec;20(12):1863-9.
  65. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996 May;30(5):359-71.
  66. Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993 Oct;16(10):1387-90.
  67. Hays JH, Gorman RT, Shakir KM. Results of use of metformin and replacement of starch with saturated fat in diets of patients with type 2 diabetes. Endocr Pract. 2002 May-Jun;8(3):177-83.
  68. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991 Nov;73(5):1016-25.
  69. de Lignieres B. Andropause and its management in the aged male. Presse Med. 2002 Novv 23;31(37 Pt 1):1750-9.
  70. Channer KS, Jones TH. Cardiovascular effects of testosterone: implications of the “male menopause”? Heart. 2003 Feb;89(2):121-2.
  71. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003 Jan;51(1):101-15.
  72. de Kruif P. The Male Hormone. New York: Harcourt, Brace and Co.; 1945.
  73. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses. 2001 Jun;56(6):702-8.
  74. Zumoff B. Hormonal abnormalities in obesity. Acta Med Scand Suppl. 1988;723:153-60.
  75. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002 Jun;5(2):98-102.
  76. Novak A, Brod M, Elbers J. Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas. 2002 Dec 10;43(4):231-7.
  77. Padula GD, Zelefsky MJ, Venkatraman ES, et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):439-43.
  78. Wu CY, Yu TJ, Chen MJ. Age related testosterone level changes and male andropause syndrome. Changgeng Yi Xue Za Zhi. 2000 Jun;23(6):348-53.
  79. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004 May;6(3):208-15.
  80. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord. 2000 Apr;24(4):485-91.
  81. Couillard C, Gagnon J, Bergeron J, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab. 2000 Mar;85(3):1026-31.
  82. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999;22(5 Suppl):110-6.
  83. Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab. 1998 Oct;12(3):441-51.
  84. Marin P. Testosterone and regional fat distribution. Obes Res. 1995 Nov;3 Suppl 4:609S-12S.
  85. Lovejoy JC, Bray GA, Gleason CS, et al. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord. 1995 Sep;19(9):614-24.
  86. Tchernof A, Despres J, Belanger A, et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism. 1995 Apr;44(4):513-9.
  87. Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord. 1993 Nov;17(11):643-9.
  88. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol. 1992 Sep;2(5):675-82.
  89. Rebuffe-Scrive M, Marin P, Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 1991 Nov;15(11):791-5.
  90. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1041-7
  91. Kley HK, Edelmann P, Kruskemper HL. Relationship of plasma sex hormones to different parameters of obesity in male subjects. Metabolism. 1980 Oct;29(11):1041-5.
  92. Killinger DW, Perel E, Daniilescu D, Kharlip L, Lindsay WR. The relationship between aromatase activity and body fat distribution. Steroids. 1987 Jul-Sep;50(1-3):61-72.
  93. Meikle AW, Stringham JD, Woodward MG, McMurry MP. Effects of a fat-containing meal on sex hormones in men. Metabolism. 1990 Sep;39(9):943-6.
  94. Awad AB, Hartati MS, Fink C. Phytosterol feeding induces alteration in testosterone metabolism in rat tissues. J Nutr Biochem. 1998 Dec;9(12):712-7.
  95. Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and estrogens in male puberty with and without gynecomastia. Clin Endocrinology. 1975 Nov; 11(5): 505-22.
  96. Gavaler JS, Van Thiel DH. The association between moderate alcoholic beverage consumption and serum estradiol and testosterone levels in normal postmenopausal women: relationship to the literature. Alcohol Clin Exp Res. 1992 Feb;16(1):87-92.
  97. Om AS,Chung KW. Dietary zinc deficiency alters 5-alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver. J Nutr.1996 Apr;126(4):842-8.
  98. Bjorntorp P. Classification of obese patients and complications related to the distribution of surplus fat. Nutrition. 1990 Mar-Apr;6 (2):131-7.
  99. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest. 1997 Oct 1;100(7):1755-9.
  100. Arlt W, Haas J, Callies F, et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab. 1999 Jun;84(6):2170-6.
  101. Delos S, Carsol JL, Ghazarossian E, Raynaud JP, Martin PM. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):375-83.
  102. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998 Feb;159(2):441-3.
  103. Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol. 1996 Aug;156(2 Pt 1):438-41.
  104. Blum I, Marilus R, Barasch E, Sztern M, Bruhis S, Kaufman H. Severe sexual impairment produced by morbid obesity. Report of a case. Int J Obes. 1988;12(3):185-9.
  105. Marques-Vidal P, Sie P, Cambou JP, Chap H, Perret B. Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab. 1995 Jun;80(6):1794-8.
  106. Lichtenstein MJ, Yarnell JW, Elwood PC, et al. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol. 1987 Oct;126(4):647-57.
  107. Winters SJ. Current status of testosterone replacement therapy in men. Arch Fam Med. 1999 May-Jun;8(3):257-63.
  108. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999 Aug;84(8):2647-53.
  109. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with “high-normal” TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol. 1998 Feb;138(2):141-5.
  110. Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symp toms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ. 2001 Oct 20;323(7318):891-5.
  111. Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and obesity. Am J Clin Nutr. 2002 Jul;76(1):281S-5S.
  112. Wheeler ML, Delahanty L, Wylie-Rosett J. Diet and exercise in noninsulin-dependent diabetes mellitus: implications for dietitians from the NIH Consensus Development Conference. Am Diet Assoc. 1987 Apr;87(4):480-5
  113. Beheri Burgess BR. Rationale for changes in the dietary management of diabetes. Fat, carbohydrate, and fiber. J Am Diet Assoc. 1982 Sep;81(3):258-61.
  114. Pawlak DB, Ebbeling CB, Ludwig DS. Should obese patients be counselled to follow a low-glycaemic index diet? Yes. Obes Rev. 2002 Nov;3(4):235-43.
  115. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest. 1998 Jun;28(6):441-6.
  116. MB Davidson, AL Peters. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997Jan;102(1):99-110.
  117. David Maggs of Yale University. Annual meeting of the American Diabetes Association. Boston, MA. November, 1997.
  118. Pugh J. Metformin monotherapy for type II diabetes. Adv Ther 1997 Nov-Dec;14(6):338-47.
  119. T Sir, T Castillo, S Munoz, G Lopez, M Calvillan. Effects of metformin on insulin resistance in obese and hyperandrogenic women. Rev Med Chil.1997 Dec;125(12):1457-63.
  120. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 1998 Apr;83(4):1143-50.
  121. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997 Sep;90(3):392-5.
  122. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998 Apr;69(4):691-6.
  123. Nestler JE, Jakubow DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in polycystic ovary syndrome. N Engl J Med. 1998 Jun 25;338(26):1876-80.
  124. Mauras N, Welch S, Rini A, Haymond HW. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: A metabolic study. J Clin Endocrinol Metab. 1998 Jun;83(6):1900-5.
  125. Nestler JE, Jakubowicz DJ, Falcon A, Brik VC, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998 Jun;83(6):2001-5.